Pacific Biosciences of California, Inc. - Common Stock (NQ:PACB)

2.540 +0.030 (+1.20%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacific Biosciences of California, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

1 Healthcare Stock to Keep an Eye On and 2 to Be Wary Of

July 07, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...

Via StockStory

Topics Stocks

3 Unprofitable Stocks Walking a Fine Line

July 02, 2025

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Via StockStory

Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock ↗

June 25, 2025

Via Benzinga

3 Stocks Under $10 with Open Questions

June 19, 2025

Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be...

Via StockStory

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

PacBio Stock Soars On Plans To Reduce Spending Over NIH Funding Uncertainty, Tariffs: Retail Is Overjoyed ↗

April 09, 2025

Via Stocktwits

Where Pacific Biosciences Stands With Analysts ↗

February 18, 2025

Via Benzinga

The RealReal, Carnival, PacBio, Quest Resource, and Hudson Technologies Shares Are Soaring, What You Need To Know

June 16, 2025

A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran.

Via StockStory

Topics Artificial Intelligence Economy Stocks

12 Health Care Stocks Moving In Friday's After-Market Session ↗

June 13, 2025

Via Benzinga

PACB Q1 Earnings Call: Cost Reductions and Clinical Adoption Offset Market Headwinds

June 10, 2025

Genomics company Pacific Biosciences of California (NASDAQ:PACB) announced better-than-expected revenue in Q1 CY2025, but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15...

Via StockStory

Topics World Trade

Q1 Earnings Roundup: PacBio (NASDAQ:PACB) And The Rest Of The Life Sciences Tools & Services Segment

June 04, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at life sciences tools & services stocks,...

Via StockStory

Topics Artificial Intelligence

3 Out-of-Favor Stocks Skating on Thin Ice

May 26, 2025

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling...

Via StockStory

Topics Supply Chain

Where Pacific Biosciences Stands With Analysts ↗

May 15, 2025

Via Benzinga

1 Russell 2000 Stock with Exciting Potential and 2 to Approach with Caution

May 14, 2025

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...

Via StockStory

PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1

May 08, 2025

Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 4.3% year on year to $37.15 million. Its...

Via StockStory

PacBio (PACB) Q1 Earnings: What To Expect

May 07, 2025

Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting results tomorrow after market close. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant ↗

April 30, 2025

On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs.

Via Benzinga

1 Volatile Stock to Target This Week and 2 to Keep Off Your Radar

April 28, 2025

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced...

Via StockStory

Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks

April 18, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Illumina (NASDAQ:ILMN) and the...

Via StockStory

Topics Artificial Intelligence

PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

April 09, 2025

A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most...

Via StockStory

Topics Artificial Intelligence Government World Trade

Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs ↗

April 09, 2025

PacBio reaffirms 2025 revenue outlook and unveils cost-cutting measures as Vega system demand grows and Revio usage meets expectations.

Via Benzinga

Simply Good Foods, Pacific Biosciences of California, Kura Sushi, Delta Air Lines And Other Big Stocks Moving Higher On Wednesday ↗

April 09, 2025

Via Benzinga

Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks

April 09, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers.

Via StockStory

Topics Artificial Intelligence

Assessing Pacific Biosciences: Insights From 6 Financial Analysts ↗

March 25, 2025

Via Benzinga

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen ↗

March 22, 2025

Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.

Via Benzinga

3 Reasons to Sell PACB and 1 Stock to Buy Instead

March 18, 2025

Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 35.2% and now trades at $1.25. This was partly due to its softer quarterly results and might...

Via StockStory

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

March 17, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.

Via StockStory

Topics Artificial Intelligence

1 Healthcare Stock to Target This Week and 2 to Turn Down

March 11, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday ↗

February 14, 2025

Via Benzinga

PacBio (NASDAQ:PACB) Misses Q4 Sales Targets

February 13, 2025

Genomics company Pacific Biosciences of California (NASDAQ:PACB) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP loss of...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.